Table 1 Relationship between the expressions of PD-1, PD-L1 and PD-L2 and clinicopathological parameters in the whole cohort
| Â | PD-1 | P Value | PD-L1 | P Value | PD-L2 | P Vaule | |||
|---|---|---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | Positive | Negative | ||||
Total | 76(46.6) | 87(53.4) | Â | 53(32.5) | 110(67.5) | Â | 43(26.4) | 120(73.6) | Â |
Age, n (%) | Â | Â | 0.65 | Â | Â | 0.27 | Â | Â | 0.35 |
 < 50y | 27(49.1) | 28(50.9) |  | 21(38.2) | 34(61.8) |  | 17(30.9) | 38(69.1) |  |
 ≥ 50y | 49(45.4) | 59(54.6) |  | 32(29.6) | 76(70.4) |  | 26(24.1) | 82(75.9) |  |
Gender, n (%) | Â | Â | 0.97 | Â | Â | 0.18 | Â | Â | 0.16 |
 Male | 50(46.7) | 57(53.3) |  | 31(29.0) | 76(71.0) |  | 32(29.9) | 75(70.1) |  |
 Female | 26(46.4) | 30(53.6) |  | 22(39.3) | 34(60.7) |  | 11(19.6) | 45(80.4) |  |
ISUP, n (%) | Â | Â | 0.13 | Â | Â | 0.81 | Â | Â | 0.57 |
 < 3 | 12(34.3) | 23(65.7) |  | 9(25.7) | 26(74.3) |  | 7(20.0) | 28(80.0) |  |
 ≥ 3 | 55(50.0) | 55(50.0) |  | 40(36.4) | 70(63.6) |  | 30(27.3) | 80(72.7) |  |
Histological Type, n(%) | Â | Â | 0.22 | Â | Â | 0.78 | Â | Â | 0.52 |
 ccRCC | 56(44.1) | 71(55.9) |  | 42(33.1) | 85(66.9) |  | 32(25.2) | 95(74.8) |  |
 Non-ccRCC | 20(55.6) | 16(44.4) |  | 11(30.6) | 25(69.4) |  | 11(30.6) | 25(69.4) |  |
Pathology, n (%) | |||||||||
 Sarcoma | 7(87.5) | 1(12.5) | 0.07 | 4(50.0) | 4(50.0) | 0.66 | 3(37.5) | 5(62.5) | 0.69 |
 Necrosis | 19(63.3) | 11(36.7) | 0.59 | 11(36.7) | 19(63.3) | 0.33 | 6(20.0) | 24(80.0) | 0.09 |
Nephrectomy | Â | Â | 0.22 | Â | Â | 0.18 | Â | Â | 0.02 |
 Yes | 68(49.6) | 69(50.4) |  | 48(35.0) | 89(65.0) |  | 39(28.5) | 98(71.5) |  |
 No | 7(35.0) | 13(65.0) |  | 4(20.0) | 16(80.0) |  | 1(5.0) | 19(95.0) |  |
ECOG, n (%) | Â | Â | 0.77 | Â | Â | 0.15 | Â | Â | 0.62 |
 0–1 | 53(47.3) | 59(52.7) |  | 42(37.5) | 70(62.5) |  | 29(25.9) | 83(74.1) |  |
 ≥ 2 | 20(50.0) | 20(50.0) |  | 10(25.0) | 30(75.0) |  | 12(30.0) | 28(70.0) |  |
IMDC, n (%) | Â | Â | 0.11 | Â | Â | 0.26 | Â | Â | 0.83 |
 Low | 10(30.3) | 23(69.7) |  | 9(27.3) | 24(72.7) |  | 9(27.3) | 24(72.7) |  |
 Intermediate | 41(51.3) | 39(48.8) |  | 29(36.3) | 51(63.7) |  | 19(23.8) | 61(76.2) |  |
 High | 15(51.7) | 14(48.3) |  | 6(20.7) | 23(79.3) |  | 6(20.7) | 23(79.3) |  |
T stage, n (%) | Â | Â | 0.691 | Â | Â | 0.09 | Â | Â | 0.91 |
 < 3 | 43(58.9) | 30(41.1) |  | 31(42.5) | 42(57.5) |  | 20(27.4) | 53(72.6) |  |
 ≥ 3 | 14(43.8) | 18(56.2) |  | 5(22.7) | 17(77.3) |  | 6(27.3) | 16(72.7) |  |
Metastasis, n (%) | |||||||||
 Lung | 13(54.2) | 11(45.8) | 0.46 | 11(45.8) | 13(54.2) | 0.21 | 7(29.2) | 17(70.8) | 0.91 |
 Lymph node | 37(77.1) | 11(22.9) | < 0.001 | 23(47.9) | 25(52.1) | 0.02 | 18(37.5) | 30(62.5) | 0.09 |
 Bone | 18(43.9) | 23(56.1) | 0.64 | 6(14.6) | 35(85.4) | 0.002 | 10(24.4) | 31(75.6) | 0.54 |
 Brain | 2(10.5) | 17(89.5) | 0.001 | 7(36.8) | 12(63.2) | 0.82 | 2(10.5) | 17(89.5) | 0.07 |
 Adrenal | 1(16.7) | 5(83.3) | 0.13 | 1(16.7) | 5(83.3) | 0.35 | 3(50.0) | 3(50.0) | 0.23 |
 Viscera | 3(18.8) | 13(81.3) | 0.02 | 5(31.3) | 11(68.8) | 0.78 | 6(37.5) | 10(62.5) | 0.38 |
 Others | 8(40.0) | 12(60.0) | 0.49 | 7(35.0) | 13(65.0) | 0.96 | 3(15.0) | 17(85.0) | 0.16 |
Treatment, n (%) | |||||||||
 Cytokine | 11(50.0) | 11(50.0) | 0.76 | 4(18.2) | 18(81.8) | 0.09 | 8(36.4) | 14(63.6) | 0.23 |
 Targeted therapy | 32(50.0) | 32(50.0) | 0.49 | 24(37.5) | 40(62.5) | 0.54 | 15(23.4) | 49(76.6) | 0.83 |
 Radiotherapy | 7(50.0) | 7(50.0) | 0.81 | 4(28.6) | 10(71.4) | 0.69 | 3(21.4) | 11(78.6) | 0.79 |
 Chemotherapy | 4(50.0) | 4(50.0) | 0.89 | 4(50.0) | 4(50.0) | 0.34 | 3(37.5) | 5(62.5) | 0.39 |